Læknablaðið - 15.01.1997, Qupperneq 29

LÆKNABLAÐIÐ 1997; 83
29
leptic Therapy in Chronic Schizophrenic Patients: Drug
and Social Consequences. Acta Psychiatr Scand 1983;
67; 339-52.
51. Kane JM, Woemer M, Liberman J, Kinon B. Tardive
Dyskinesia. In: Jeste DV, Wyatt RJ, eds. Neuropsychia-
tric Movement Disorders. Washington, DC: American
Psychiatric Press, 1984: 98-118.
52. Kane JM, Smith JM. Tardive Dyskinesia: Prevalence
and Risk Factors, 1959 to 1979. Arch Gen Psychiatry
1982; 39: 473-81.
53. Morgenstern H, Glazer WM. Identifying Risk Factors
for Tardive Dyskinesia Among Long-term Outpatients
Maintained With Neuroleptic Medications. Arch Gen
Psychiatry 1993; 50: 723-33.
54. Sweet RA, Mulsant BH, Gupta B, Rifai AH, Pasternak
RE, McEachran A, et al. Duration of Neuroleptic
Treatment and Prevalence of Tardive Dyskinesia in Late
Life. Arch Gen Psychiatry 1995; 52: 478-86.
55. Jeste PV, Caligiuri MP, Paulsen JS, Heaton RK, Lacro
JP, Harris MJ, et al. Risk of Tardive Dyskinesia in Older
Patients. Arch Gen Psychiatry 1995; 52: 756-65.
56. Kramer MS, Vogel WH, DiJohnson C, Dewey DA,
Sheves P, Caviccia S, et al. Antidepressants in “de-
pressed” schizophrenic inpatients. Arch Gen Psychiatry
1989; 46: 922-8.
57. SirisS, Morgan V, FagerstromR, Rifkin A, CooperTB.
Adjunctive imipramin in the treatment of postpsychotic
depression. Arch Gen Psychiatry 1987; 44: 533-9.
58. Siris SG, Bermanzohn PC, Mason SE, Shuwall MA.
Maintenance Imipramine Theraphy for Secundary De-
pression in Schizophrenia: a Controlled Trial. Arch Gen
Psychiatry 1994; 51: 109-15.
59. Hogarty GE, McEvoy JP, Ulrich RF, DiBarry AL, Bar-
tone P, Cooley S, et al. Pharmacotherapy of Impaired
Affect in Recovering Schizophrenic Patients. Arch Gen
Psychiatry 1995; 52: 29-41.
60. Mayer-Gross. In: Slater E, Roth M, eds. Clinical Psychi-
atry. 3rd ed. London: Bailliére Tindall, 1977: 285-6.
61. Caroff SN.Mann SC. NeurolepticMalignant Syndrome.
Med Clin North Am 1993; 77: 185-202.
62. Heiman-Patterson TD. Neuroleptic Malignant Syn-
drome and Malignant Hyperthermia. Med Clin North
Am 1993; 77: 477-92.
63. Dickey W. The Neuroleptic Malignant Syndrome. Prog
Neurobiol 1991; 36: 425-36.
64. Castillo E, Rubin RT, Holsboer-Trachsler E. Clinical
Differentiation Between Lethal Catatonia and Neuro-
leptic Malignant Syndrome. Am J Psychiatry 1989; 146:
324-8.
65. Rosebush P, Stewart T. A Prospective Analysis of 24
Episodes of Neuroleptic Malignant Syndrome. Am J
Psychiatry 1989; 146: 717-25.
66. Shalev A, Hermesh H, Munitz H. Mortality from Neu-
rolepticMalignant Syndrome. J ClinPsychiatry 1989; 50:
18-25.
67. Deng MZ, Chen GQ, Phillips MR. Neuroleptic Malig-
nant Syndrome in 12 of 9792 Chinese Inpatients Exposed
to Neuroleptics: a Prospective Study. Am J Psychiatry
1990; 147: 1149-55.
68. Gelenberg AJ, Bellinghausen B, Wojcik JD, Falk WE,
Sachs GS. A Prospectic Survey of Neuroleptic Malig-
nant Syndrome in a Short-term Psychiatric Hospital.
Am J Psychiatry 1988; 145: 517-8.
69. Keck PE Jr, McElroy SL, Pope HG Jr. Epidemiology of
Neuroleptic Malignant Syndrome. Psychiatr Ann 1991;
21: 148-51.
70. Addonizio G, Susman VL, Roth SD. NeurolepticMalig-
nant Syndrome: Review and Analysis of 115 Cases. Biol
Psychiatry 1987; 22: 1004-20.
71. Lin KM, Poland RE, Nuccio I, Matsuda K, Hathuc N,
Su TP, et al. A Longitudional Assesment of Haloperidol
Doses and Serum Concentrations in Asian and Cauca-
sian Schizophrenic patients. Am J Psychiatry 1989; 146:
1307-11.
72. Keck PE, Pope HG, Cohen BM. Risk Factors for Neu-
roleptic Malignant Syndrome. Arch Gen Psychiatry
1989; 46: 914-8.
73. Keck PE, Pope HG, McElroy SL. Frequency and Pre-
sentation of Neuroleptic Malignant Syndrome: a Pro-
spective Study. Am J Psychiatry 1987; 144: 1344-6.
74. Keck PE, Pope HG, McElroy SL. Declining Frequency
of Neuroleptic Malignant Syndrome in a Hospital Pop-
ulation. Am J Psychiatry 1991; 148: 880-2.